2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease

Benjamin Besse; A. Adjei; P. Baas; P. Meldgaard; M. Nicolson; L. Paz-Ares; M. Reck; E. F. Smit; Konstantinos Syrigos; R. Stahel; E. Felip; S. Peters; Keith Kerr; Johan Vansteenkiste; Wilfried Eberhardt; Martin Edelman; Tony Mok; Ken O'Byrne; Silvia Novello; Lukas Bubendorf; Antonio Marchetti; Paul Baas; Martin Reck; Peter Meldgaard; Alex Adjei; Marianne Nicolson; Lucio Crinò; Paul Van Schil; Suresh Senan; Corinne Faivre-Finn; Gaetano Rocco; Giulia Veronesi; Jean Yves Douillard; Eric Lim; Christophe Dooms; Walter Weder; Dirk De Ruysscher; Cecile Le Pechoux; Paul De Leyn; Virginie Westeel

doi:10.1093/annonc/mdu123

2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease

Benjamin Besse, A. Adjei, P. Baas, P. Meldgaard, M. Nicolson, L. Paz-Ares, M. Reck, E. F. Smit, Konstantinos Syrigos, R. Stahel, E. Felip, S. Peters, Keith Kerr, Johan Vansteenkiste, Wilfried Eberhardt, Martin Edelman, Tony Mok, Ken O'Byrne, Silvia Novello, Lukas BubendorfAntonio Marchetti, Paul Baas, Martin Reck, Peter Meldgaard, Alex Adjei, Marianne Nicolson, Lucio Crinò, Paul Van Schil, Suresh Senan, Corinne Faivre-Finn, Gaetano Rocco, Giulia Veronesi, Jean Yves Douillard, Eric Lim, Christophe Dooms, Walter Weder, Dirk De Ruysscher, Cecile Le Pechoux, Paul De Leyn, Virginie Westeel

Research output: Contribution to journal › Article › peer-review

219 Scopus citations

Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early stage disease and locally-advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on 1^st line / 2^nd and further lines of treatment in advanced disease.

Original language	English
Pages (from-to)	1475-1484
Number of pages	10
Journal	Annals of Oncology
Volume	25
Issue number	8
DOIs	https://doi.org/10.1093/annonc/mdu123
State	Published - Aug 1 2014

Keywords

Age Factors
Aged
Angiogenesis Inhibitors/therapeutic use
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Carboplatin/administration & dosage
Carcinoma, Non-Small-Cell Lung/drug therapy
Chemotherapy, Adjuvant/methods
Cisplatin/administration & dosage
Combined Modality Therapy/methods
Consensus
Drug Substitution/methods
Humans
Lung Neoplasms/drug therapy
Maintenance Chemotherapy/standards
Neoadjuvant Therapy/methods

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdu123

Cite this

Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M., Paz-Ares, L., Reck, M., Smit, E. F., Syrigos, K., Stahel, R., Felip, E., Peters, S., Kerr, K., Vansteenkiste, J., Eberhardt, W., Edelman, M., Mok, T., O'Byrne, K., Novello, S., ... Westeel, V. (2014). 2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease. Annals of Oncology, 25(8), 1475-1484. https://doi.org/10.1093/annonc/mdu123

@article{4317eded91ee4a41a1e6750d4d7c1394,

title = "2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease",

abstract = "To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early stage disease and locally-advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on 1st line / 2nd and further lines of treatment in advanced disease.",

keywords = "Age Factors, Aged, Angiogenesis Inhibitors/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carboplatin/administration & dosage, Carcinoma, Non-Small-Cell Lung/drug therapy, Chemotherapy, Adjuvant/methods, Cisplatin/administration & dosage, Combined Modality Therapy/methods, Consensus, Drug Substitution/methods, Humans, Lung Neoplasms/drug therapy, Maintenance Chemotherapy/standards, Neoadjuvant Therapy/methods",

author = "Benjamin Besse and A. Adjei and P. Baas and P. Meldgaard and M. Nicolson and L. Paz-Ares and M. Reck and Smit, {E. F.} and Konstantinos Syrigos and R. Stahel and E. Felip and S. Peters and Keith Kerr and Johan Vansteenkiste and Wilfried Eberhardt and Martin Edelman and Tony Mok and Ken O'Byrne and Silvia Novello and Lukas Bubendorf and Antonio Marchetti and Paul Baas and Martin Reck and Peter Meldgaard and Alex Adjei and Marianne Nicolson and Lucio Crin{\`o} and {Van Schil}, Paul and Suresh Senan and Corinne Faivre-Finn and Gaetano Rocco and Giulia Veronesi and Douillard, {Jean Yves} and Eric Lim and Christophe Dooms and Walter Weder and {De Ruysscher}, Dirk and {Le Pechoux}, Cecile and {De Leyn}, Paul and Virginie Westeel",

note = "{\textcopyright} The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].",

year = "2014",

month = aug,

day = "1",

doi = "10.1093/annonc/mdu123",

language = "English",

volume = "25",

pages = "1475--1484",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "8",

}

Besse, B, Adjei, A, Baas, P, Meldgaard, P, Nicolson, M, Paz-Ares, L, Reck, M, Smit, EF, Syrigos, K, Stahel, R, Felip, E, Peters, S, Kerr, K, Vansteenkiste, J, Eberhardt, W, Edelman, M, Mok, T, O'Byrne, K, Novello, S, Bubendorf, L, Marchetti, A, Baas, P, Reck, M, Meldgaard, P, Adjei, A, Nicolson, M, Crinò, L, Van Schil, P, Senan, S, Faivre-Finn, C, Rocco, G, Veronesi, G, Douillard, JY, Lim, E, Dooms, C, Weder, W, De Ruysscher, D, Le Pechoux, C, De Leyn, P & Westeel, V 2014, '2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease', Annals of Oncology, vol. 25, no. 8, pp. 1475-1484. https://doi.org/10.1093/annonc/mdu123

TY - JOUR

T1 - 2nd ESMO Consensus Conference on Lung Cancer

T2 - Non-small-cell lung cancer first-line/second and further lines in advanced disease

AU - Besse, Benjamin

AU - Adjei, A.

AU - Baas, P.

AU - Meldgaard, P.

AU - Nicolson, M.

AU - Paz-Ares, L.

AU - Reck, M.

AU - Smit, E. F.

AU - Syrigos, Konstantinos

AU - Stahel, R.

AU - Felip, E.

AU - Peters, S.

AU - Kerr, Keith

AU - Vansteenkiste, Johan

AU - Eberhardt, Wilfried

AU - Edelman, Martin

AU - Mok, Tony

AU - O'Byrne, Ken

AU - Novello, Silvia

AU - Bubendorf, Lukas

AU - Marchetti, Antonio

AU - Baas, Paul

AU - Reck, Martin

AU - Meldgaard, Peter

AU - Adjei, Alex

AU - Nicolson, Marianne

AU - Crinò, Lucio

AU - Van Schil, Paul

AU - Senan, Suresh

AU - Faivre-Finn, Corinne

AU - Rocco, Gaetano

AU - Veronesi, Giulia

AU - Douillard, Jean Yves

AU - Lim, Eric

AU - Dooms, Christophe

AU - Weder, Walter

AU - De Ruysscher, Dirk

AU - Le Pechoux, Cecile

AU - De Leyn, Paul

AU - Westeel, Virginie

PY - 2014/8/1

Y1 - 2014/8/1

N2 - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early stage disease and locally-advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on 1st line / 2nd and further lines of treatment in advanced disease.

AB - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early stage disease and locally-advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on 1st line / 2nd and further lines of treatment in advanced disease.

KW - Age Factors

KW - Aged

KW - Angiogenesis Inhibitors/therapeutic use

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Carboplatin/administration & dosage

KW - Carcinoma, Non-Small-Cell Lung/drug therapy

KW - Chemotherapy, Adjuvant/methods

KW - Cisplatin/administration & dosage

KW - Combined Modality Therapy/methods

KW - Consensus

KW - Drug Substitution/methods

KW - Humans

KW - Lung Neoplasms/drug therapy

KW - Maintenance Chemotherapy/standards

KW - Neoadjuvant Therapy/methods

UR - http://www.scopus.com/inward/record.url?scp=84905195418&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdu123

DO - 10.1093/annonc/mdu123

M3 - Article

C2 - 24669016

AN - SCOPUS:84905195418

SN - 0923-7534

VL - 25

SP - 1475

EP - 1484

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -

2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this